Reports Q3 revenue $8.556M, consensus $6.37M. “The third quarter was highlighted by strong commercial execution of the VYJUVEK launch, advancement of the oncology program into the clinic and continued momentum in the CF program,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech. “With respect to the VYJUVEK launch, our guiding vision is centered around optimizing the patient experience, and we have and will continue to work tirelessly to ensure that each patient’s journey, with respect to starting on VYJUVEK and staying on it, is smooth, timely and hassle free.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on KRYS:
- Krystal Biotech Announces Third Quarter 2023 Financial Results and Provides Business Update
- KRYS Upcoming Earnings Report: What to Expect?
- Krystal Biotech initiated with an Overweight at Cantor Fitzgerald
- Krystal Biotech initiated with a Buy at Citi
- Krystal Biotech Announces FDA Clearance of Investigational New Drug Application for KB408 for the Treatment of Type 1 Alpha-1 Antitrypsin Deficiency
